Enzo Biochem (ENZ) Stock Forecast, Price & News

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment provides molecular and other clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 30 patient service centers in New York and New Jersey; and a free-standing 'STAT' or rapid response laboratories in New York City and Connecticut, as well as a full-service phlebotomy center and an in-house logistics department. The Therapeutics segment develops novel approaches in the areas of gastrointestinal, infectious, ophthalmic, and metabolic diseases. It markets its products and services through its direct sales force and a network of distributors in the United States and internationally. The company was founded in 1976 and is headquartered in New York, New York.

Wall Street Analysts Forecast Growth

ENZ has been the subject of several analyst reports. TheStreet cut shares of Enzo Biochem from a "c-" rating to a "d+" rating in a research report on Tuesday, May 17th. StockNews.com initiated coverage on shares of Enzo Biochem in a research report on Sunday, July 31st. They set a "hold" rating for the company.

Enzo Biochem Price Performance

Shares of ENZ Stock remained flat at $2.53 on Friday. The company had a trading volume of 37,901 shares, compared to its average volume of 52,967. The stock's 50 day moving average is $2.32 and its 200 day moving average is $2.73. The company has a market capitalization of $123.26 million, a PE ratio of -19.46 and a beta of 0.88. The company has a debt-to-equity ratio of 0.07, a quick ratio of 1.92 and a current ratio of 2.52. Enzo Biochem has a twelve month low of $1.98 and a twelve month high of $4.15.

Enzo Biochem (NYSE:ENZ - Get Rating) last posted its earnings results on Thursday, June 9th. The medical research company reported ($0.09) EPS for the quarter. The company had revenue of $26.22 million during the quarter. Enzo Biochem had a negative return on equity of 1.98% and a negative net margin of 5.88%.

Insider Activity at Enzo Biochem

In related news, Director Bradley Louis Radoff bought 120,000 shares of the firm's stock in a transaction on Tuesday, July 5th. The shares were purchased at an average price of $2.20 per share, with a total value of $264,000.00. Following the completion of the purchase, the director now owns 4,182,163 shares in the company, valued at approximately $9,200,758.60. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders purchased a total of 193,100 shares of company stock valued at $426,524 in the last quarter. Insiders own 17.40% of the company's stock.